The United States has seen a significant drop in opioid overdose deaths, about 50% lower than their peak in 2023. A secondary analysis using data collected from law enforcement drug seizure reports and CDC overdose death records from 2018 to 2024 compared how many people were dying from opioid overdoses each month and how often fentanyl showed up in drugs seized by law enforcement.

What Researchers Found:

As overdose deaths dropped, fentanyl became slightly less common, but not by much.

●     Overdose deaths fell from 2.2 to 1.1 deaths per 100,000 people per month (50%)

●     Fentanyl showed up in drug seizures less often, dropping from about 29% to 23%

Reviewing all the data, researchers found that lower fentanyl levels only explained about 9% of the total drop in deaths.

What Else Might Be Driving the Decline in Deaths:

At first glance, it seems logical that less fentanyl should mean fewer deaths and that’s partly true. But this study shows that most of the improvements come from other factors such as:

●     Better access to addiction treatment

●     More people carrying Naloxone (Narcan)

●     Changes in how people use drugs

●     Education and awareness about overdose risks

What This Means Going Forward:

The encouraging news is that opioid overdose deaths are declining. If we want to keep overdose deaths falling, we can’t rely on changes in the drug supply alone. We must continue to:

●     Expand treatment and recovery services

●     Continue to educate on overdose risks

●     Expand prevention education to more people

●     Make overdose-reversal drugs widely available

●     Respond to local drug trends, which can vary a lot by region

As this study makes one thing clear: progress isn’t just about fentanyl becoming less common, it likely reflects a mix of public health efforts, policy changes, and behavior shifts happening at the same time.

 

References

Dahlen A, Lei F, Agyabeng K, et al. Proportion of Fentanyl Reports in Illicit Drug Seizures and Opioid Mortality. JAMA Health Forum. 2026;7(1):e256286. doi:10.1001/jamahealthforum.2025.6286